Poster tours at #EULAR2024. A third of seropositive RA patients with long disease duration had subclinical lung abnormalities. This pilot study showed the potential role of lung ultrasound for the screening of subclinical ILD among these patients. Abstract 070 @RheumNow https://t.co/ypAh4idV3j

• https://twitter.com/synovialjoints/status/1801175696317808811/photo/1

OP0072 @RheumNow #EULAR2024 Effects of #Upadacitinib or #Adalimumab on pain in #RA SELECT-COMPARE Phase 3 study UPA & ADA led to improvements in pain vs PBO PtGA & TJC28 pain improvement similar between UPA & ADA ➡️ UPA may be more effective in control of pain than ADA in RA

#Vaccinations against #herpes #zoster in #MTX +#Upadacitinib Pts ▶️ #Shingrix works 👍Pts followed to 60 months #EULAR2024 @eular_org @RheumNow #OP0020 https://t.co/8ORC3Nd2FK

• https://twitter.com/drdavidliew/status/1800906791502647424

OP0018 @RheumNow #EULAR2024 🔎 Study looked at early RA patient trajectories through time-independent disease state 📊 Authors demonstrated 4⃣ trajectories in early RA 🦴 Inflammation in joints, blood & poor response are main discriminatory factors https://t.co/IeDIU3jg9B

• https://twitter.com/DrMiniDey/status/1800970427642298680/photo/1

➡️ OP0064 @RheumNow #EULAR2024 ➡️ Non-articular pain (NAP) at early RA diagnosis & evolution over the first yr of RA treatment ➡️ NAP, esp regional NAP, common in early RA during 1st yr ➡️ NAP in axial, both upper quadrants and both lower quadrants common https://t.co/FOGcS05Z25

• https://twitter.com/DrMiniDey/status/1800968672300892171/photo/1

OP0086 #EULAR2024 @RheumNow #EULARBest Pain & remission/low disease activity at 3m in pts with #RA in RA-BE-REAL Pts taking #baricitinib more likely to achieve pain control vs TNFi/other mode of action 1/2 pts achieving remission/LDA & had bari achieved ≥70% pain relief.

TOLERA trial in RA RTX/ABA sequence versus RTX alone 10pts each group Primary outcome was ambitious: ACPA seroconversion No difference between ttmts (and also no seroconversion) No diff in disease activity No diff in ACPA change wt wk52 @RheumNow OP0069 #EULAR2024 https://t.co/0EM7XRzfNo

• https://twitter.com/AurelieRheumo/status/1800946507190870218/photo/1

AMPLIFIED RCT, 300+ pts ABA NOT (!) superior to ADA in dual seropositive SE+ MTX IR RA pts ACR50 rate high in both gps ABA 59% vs ADA 64% No new safety signal Defeating the encouraging data from smaller trials Abstr#OP0007 #EULAR2024 @RheumNow https://t.co/PvRUnpthHl

• https://twitter.com/AurelieRheumo/status/1800938588101599607/photo/1

Reminder of relevance of #Rheumatoid factor ⬆️RF also predicts cardiovascular events ⚠️ ⬆️disease activity ❗️Worse outcomes #EULAR2024 #RF #RA https://t.co/kXwh682ONp

• https://twitter.com/gurdeep_dulay/status/1800935105009000749/photo/1

What is new in RA at #EULAR2024? Below 👇🏻 my article summarising some of the exciting new MoA, therapeutic strategies and drugs that might (or not) shape RA future! https://t.co/ttYdElWlBY @RheumNow

• Encurtador de Link

🚨New(ish) MoA in RA Abiprubart anti-CD40 mAb Blocks T cell activation Reduction DAS28-CRP Wk 12 -2.2 vs. -1.6 PBO Small sample n=25 per gpe Safety profile acceptable To be continued... Abstr#OP0036 #EULAR2024 @RheumNow https://t.co/su4L7A7nGJ

• https://twitter.com/AurelieRheumo/status/1800933979584917902/photo/1